S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
"The Most Critical Metal for Global Economies" (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
"The Most Critical Metal for Global Economies" (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
"The Most Critical Metal for Global Economies" (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
Free Webinar | October 11: How to Break Barriers
"The Most Critical Metal for Global Economies" (Ad)
Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
Live Updates: Russia-Ukraine War
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
Too Soon: 3 Reasons to Wait on DocuSign Stock
OPEC+ makes big oil cut to boost prices; pump costs may rise
Move Over Lithium – 220 Pounds of Graphite In Every EV Battery (Ad)
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Hot Potato: Lamb Weston Stock Confirms a Top 
NASDAQ:RDHL

RedHill Biopharma - RDHL Stock Forecast, Price & News

$0.65
+0.03 (+4.12%)
(As of 10/6/2022 09:15 AM ET)
Add
Compare
Today's Range
$0.64
$0.68
50-Day Range
$0.49
$1.07
52-Week Range
$0.47
$6.50
Volume
10,742 shs
Average Volume
1.67 million shs
Market Capitalization
$34.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

RedHill Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,382.0% Upside
$15.50 Price Target
Short Interest
Healthy
3.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of RedHill Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

875th out of 1,072 stocks

Pharmaceutical Preparations Industry

434th out of 534 stocks

RDHL stock logo

About RedHill Biopharma (NASDAQ:RDHL) Stock

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Stock News Headlines

A Potential Fintech Unicorn
This stock weathered the digital currency downturn and still has huge potential.
RedHill Biopharma Ltd. (RDHL)
Mr. Wonderful's DeFi Comeback
Digital currency companies dropped like flies, but this stock still stands.
See More Headlines
Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Company Calendar

Last Earnings
11/30/2021
Today
10/06/2022
Next Earnings (Estimated)
11/29/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDHL
Employees
201
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+2,283.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-97,740,000.00
Net Margins
-110.31%
Pretax Margin
-110.31%

Debt

Sales & Book Value

Annual Sales
$85.76 million
Book Value
$0.17 per share

Miscellaneous

Free Float
49,096,000
Market Cap
$34.25 million
Optionable
Optionable
Beta
1.94

Key Executives

  • Mr. Dror Ben-Asher (Age 56)
    Co-Founder, Chairman & CEO
    Comp: $884.67k
  • Mr. Micha Ben-Chorin (Age 53)
    Chief Financial Officer
    Comp: $548.14k
  • Mr. Gilead Raday MPhil (Age 47)
    MSc, Chief Operating Officer
    Comp: $539.74k
  • Mr. Adi Frish (Age 52)
    Chief Corp. & Bus. Devel. Officer
    Comp: $519.65k
  • Mr. Rick D. Scruggs (Age 62)
    Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director
    Comp: $736.35k
  • Dr. Mark L. Levitt M.D.
    Ph.D., Chief Scientific Officer
  • Ms. Alexandra Okmian
    Sr. Bus. Devel. & Investor Relations Mang.
  • Kristin Comer
    VP, Gen. Counsel & Chief Compliance Officer
  • Ms. Valerie Graceffa
    VP of Sales
  • Mr. Rob Jackson
    Sr. VP of Sales & Marketing













RDHL Stock - Frequently Asked Questions

Should I buy or sell RedHill Biopharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RedHill Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RDHL shares.
View RDHL analyst ratings
or view top-rated stocks.

What is RedHill Biopharma's stock price forecast for 2022?

2 Wall Street research analysts have issued 1-year price objectives for RedHill Biopharma's stock. Their RDHL share price forecasts range from $10.00 to $21.00. On average, they expect the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 2,382.0% from the stock's current price.
View analysts price targets for RDHL
or view top-rated stocks among Wall Street analysts.

How have RDHL shares performed in 2022?

RedHill Biopharma's stock was trading at $2.58 at the beginning of the year. Since then, RDHL shares have decreased by 75.8% and is now trading at $0.6245.
View the best growth stocks for 2022 here
.

When is RedHill Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 29th 2022.
View our RDHL earnings forecast
.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) released its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.02. The biotechnology company earned $21.61 million during the quarter, compared to analyst estimates of $23.41 million. RedHill Biopharma had a negative trailing twelve-month return on equity of 822.29% and a negative net margin of 110.31%. During the same quarter in the previous year, the company earned ($0.50) EPS.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $0.62.

How much money does RedHill Biopharma make?

RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $32.90 million and generates $85.76 million in revenue each year. The biotechnology company earns $-97,740,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does RedHill Biopharma have?

The company employs 201 workers across the globe.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144.

This page (NASDAQ:RDHL) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.